Expert Ratings for MoonLake

November 27, 2023

https://www.benzinga.com/analyst-ratings/23/11/35956543/expert-ratings-for-moonlake

https://www.benzinga.com/analyst-ratings/23/11/35956543/expert-ratings-for-moonlake

Related news for (MLTX)

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Expert Ratings for MoonLake

Related news for (MLTX)

Follow Us on Social Media

Sign Up for Our Newsletter

Related news for (MLTX)

AI Soars and Tiny Winners Take the Spotlight

Morning Market Briefing: Micro-Caps Primed for Breakouts

Morning Market Recap: Precision Medicine Clears the Path, A&D Soars, and Gaming Gets a Buyback Boost

AI, Amps & Altitude: Market Movers Rewrite the Playbook

Power Hour Power Play Stocks Poised to Light Up Today’s Close + After-Hours

Follow Us on Social Media

Sign Up for Our Newsletter